• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intracellular carbovir triphosphate levels in patients taking abacavir once a day.

作者信息

Harris Marianne, Back David, Kewn Sean, Jutha Salima, Marina Raymond, Montaner Julio S G

出版信息

AIDS. 2002 May 24;16(8):1196-7. doi: 10.1097/00002030-200205240-00021.

DOI:10.1097/00002030-200205240-00021
PMID:12004286
Abstract
摘要

相似文献

1
Intracellular carbovir triphosphate levels in patients taking abacavir once a day.每天服用一次阿巴卡韦的患者细胞内卡波韦三磷酸水平。
AIDS. 2002 May 24;16(8):1196-7. doi: 10.1097/00002030-200205240-00021.
2
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.在人类免疫缺陷病毒感染受试者中，每日一次服用600毫克阿巴卡韦和每日两次服用300毫克阿巴卡韦后，阿巴卡韦在血浆和细胞内三磷酸卡波韦的稳态药代动力学。
Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8. doi: 10.1128/AAC.01000-08. Epub 2009 Feb 2.
3
Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.通过液相色谱-正离子电喷雾串联质谱法提高核苷酸测量的特异性：应用于定量测定人外周血单核细胞中的卡波韦三磷酸酯、拉米夫定三磷酸酯和替诺福韦二磷酸酯。
J Mass Spectrom. 2008 Feb;43(2):224-33. doi: 10.1002/jms.1294.
4
Interlaboratory measurement differences in intracellular carbovir triphosphate concentrations in HIV-infected patients: sources of variability in processing, shipping, and quantitation.
J Clin Pharmacol. 2010 Aug;50(8):968-74. doi: 10.1177/0091270009352186. Epub 2009 Dec 1.
5
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.在ARROW试验中，乌干达1型艾滋病毒感染儿童每日一次与每日两次服用拉米夫定和阿巴卡韦的药代动力学及可接受性
Antivir Ther. 2010;15(8):1115-24. doi: 10.3851/IMP1695.
6
Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.阿巴卡韦在HIV-1感染的青少年和年轻成年人长期治疗期间的药代动力学。
Clin Pharmacol Ther. 2009 Apr;85(4):394-401. doi: 10.1038/clpt.2008.236. Epub 2008 Dec 31.
7
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.阿巴卡韦在未感染和感染人类免疫缺陷病毒（HIV）的患者中，分别在不存在和存在阿扎那韦/利托那韦或洛匹那韦/利托那韦的情况下的血浆药代动力学，反之亦然。
Antivir Ther. 2007;12(5):825-30.
8
Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5'-triphosphate metabolite levels.阿巴卡韦（ABC）的芳氧基甲氧基丙氨酰氨基磷酸酯（APA）前药抗病毒活性增强是由于显著提高了卡波韦5'-三磷酸代谢物水平的形成。
FEBS Lett. 2004 Aug 27;573(1-3):38-44. doi: 10.1016/j.febslet.2004.07.049.
9
Abacavir sulfate.
J Assoc Nurses AIDS Care. 2000 Nov-Dec;11(6):72-5. doi: 10.1016/S1055-3290(06)60358-0.
10
Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.对三磷酸卡波韦抑制HIV-1逆转录酶及耐药性分子机制的见解。
Biochemistry. 2002 Apr 23;41(16):5150-62. doi: 10.1021/bi0121858.

引用本文的文献

1
Examining the effects of the HIV-1 protein Tat and morphine on antiretroviral accumulation and distribution within the brain.检测 HIV-1 蛋白 Tat 和吗啡对大脑内抗逆转录病毒积累和分布的影响。
Clin Transl Sci. 2024 Oct;17(10):e70035. doi: 10.1111/cts.70035.
2
Abacavir Increases Purinergic P2X7 Receptor Activation by ATP: Does a Pro-inflammatory Synergism Underlie Its Cardiovascular Toxicity?阿巴卡韦增强ATP对嘌呤能P2X7受体的激活作用：促炎协同作用是其心血管毒性的潜在原因吗？
Front Pharmacol. 2021 Mar 31;12:613449. doi: 10.3389/fphar.2021.613449. eCollection 2021.
3
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.
健康志愿者每日口服 300 毫克和 150 毫克拉米夫定后的拉米夫定及其三磷酸盐的药代动力学：ENCORE 2 研究结果。
Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33. doi: 10.1128/AAC.05599-11. Epub 2011 Dec 19.
4
Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.阿巴卡韦通过竞争性抑制可溶性鸟苷酸环化酶增加血小板反应性。
AIDS. 2011 Nov 28;25(18):2243-8. doi: 10.1097/QAD.0b013e32834d3cc3.
5
Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.抗 HIV 核苷类似物代谢物细胞内蓄积个体差异的决定因素。
Antimicrob Agents Chemother. 2011 Feb;55(2):895-903. doi: 10.1128/AAC.01303-10. Epub 2010 Nov 15.
6
Abacavir/lamivudine combination in the treatment of HIV: a review.阿巴卡韦/拉米夫定联合治疗 HIV：综述。
Ther Clin Risk Manag. 2010 Mar 3;6:83-94. doi: 10.2147/tcrm.s1657.
7
Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.阿巴卡韦/拉米夫定固定剂量复方抗逆转录病毒治疗艾滋病。
Adv Ther. 2010 Jan;27(1):1-16. doi: 10.1007/s12325-010-0006-9. Epub 2010 Mar 5.
8
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.HIV 感染患者体内抗逆转录病毒药物的药代动力学及其与药物作用的相关性。
Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000.
9
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.接受富马酸替诺福韦二吡呋酯（TDF）的人类免疫缺陷病毒感染患者的药代动力学初步研究：TDF与阿巴卡韦、拉米夫定或洛匹那韦-利托那韦之间的全身和细胞内相互作用研究
Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.
10
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.在人类免疫缺陷病毒感染受试者中，每日一次服用600毫克阿巴卡韦和每日两次服用300毫克阿巴卡韦后，阿巴卡韦在血浆和细胞内三磷酸卡波韦的稳态药代动力学。
Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8. doi: 10.1128/AAC.01000-08. Epub 2009 Feb 2.